NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. ("Sanara" or the "Company") (NASDAQ: SMTI). Such investors are advised...
NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. ("Sanara" or the "Company") (NASDAQ: SMTI). Such investors are advised...
Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter FORT WORTH, TX, May 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech...
NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. ("Sanara" or the "Company") (NASDAQ: SMTI). Such investors are advised...
NEW YORK , April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. ("Sanara" or the "Company") (NASDAQ: SMTI). Such investors are advised...
FORT WORTH, TX, April 14, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company”, “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing...
FORT WORTH, TX, March 24, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing...
Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX ® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the...
FORT WORTH, TX, March 03, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing...
FORT WORTH, TX, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing...